| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to new compounds of formula (I) and to their pharmaceutically acceptable salts exhibiting P2X 3 receptor antagonist activity. In formula (I), X represents -O-; Y represents -NR d R e where one of radicals R d and R e means hydrogen, and the other means hydrogen; C 1 -C 12 alkyl; C 5 -C 7 cycloalkyl; C 5 -C 7 cycloalky-C 1 -C 12 alkyl; hydroxy-C 1 -C 12 alkyl; acetyl; aminocarbonyloxy- C 1 -C 12 alkyl or heterocyclyl representing a 6-members saturated ring containing heteroatom S substituted by two oxo groups; D represents optional oxygen; R 1 represents isopropyl; R 2 represents hydrogen; R 5 represents hydrogen or C 1 -C 12 alkyl; R 4 means hydrogen; C 1 -C 12 alkyl; halogen; halogen- C 1 -C 12 alkyl; C 1 -C 12 alkoxy; hydroxy; halogen- C 1 -C 12 alkoxy; nitro; amino; hydroxy- C 1 -C 12 alkyl; C 1 -C 12 alkoxyalkyl; hydroxy- C 1 -C 12 alkoxy; C 1 -C 12 alkylsulphonyl; cyano; heteroaryl representing a 5-members aromatic ring containing one, two or three heteroatoms selected from O, S and N which can be optionally substituted by a thio group, C 1 -C 12 alkyl or C 1 -C 12 alkylsulphonyl; heterocyclyl representing a 6-members saturated ring containing two heteroatoms N, one of which is substituted C 1 -C 12 alkylsulphonyl; -(CH 2 ) m -(Z)n-(CO)-R f or -(CH 2 ) m -(Z) n -SO 2 -(NR g ) n -R f where each m and n independently represents 0 or 1, Z means NR 8 , R f means C 1 -C 12 alkyl, hydroxy, amino or hydroxy- C 1 -C 12 alkyl, and R g means hydrogen; R 3 represents methoxy; R 6 represents hydrogen; and one of radicals R 7 and R 8 represents hydrogen, and the other represents hydrogen, acetyl or phenyl. n EFFECT: also, the invention refers to a pharmaceutical composition and to an application of the compound of formula (I) for preparing a drug. n 8 cl, 3 tbl, 70 ex |